Heating tumors plus drug shows promise in early breast cancer trial

NCT ID NCT03955640

Terminated Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested a combination of hyperthermia (heating the tumor area) and the drug olaparib in 3 patients with breast cancer that had returned on the chest wall. The goal was to see if the combination was safe and could slow tumor growth. The study was terminated early, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib (a PARP inhibitor drug) and hyperthermia treatment (heating the tumor area)
What this could lead to: If it works, this could point toward a new combination treatment for breast cancer that has come back on the chest wall.
What could go wrong: This was a very small, early-phase trial with only 3 patients, and it was terminated early. The combination may not be safe or effective, and results are too limited to draw conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER WITH CHEST WALL RECURRENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm malignant neoplasm of chest wall

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MALIGNANT NEOPLASM IN THE CHEST WALL RECURRENT BREAST CARCINOMA

Contacts and locations

Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.